Evidence map›Paper›PMID 35433657›Full record

ArticleFrontiers in bioengineering and biotechnology2022

Endothelial Progenitor Cell-Based

Sarah E Motta, Polina Zaytseva, Emanuela S Fioretta, Valentina Lintas, Christian Breymann, Simon P Hoerstrup, Maximilian Y Emmert

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Sarah E MottaInstitute for Regenerative Medicine (IREM), University of Zurich, Zurich, Switzerland.
Polina ZaytsevaInstitute for Regenerative Medicine (IREM), University of Zurich, Zurich, Switzerland.
Emanuela S FiorettaInstitute for Regenerative Medicine (IREM), University of Zurich, Zurich, Switzerland.
Valentina LintasInstitute for Regenerative Medicine (IREM), University of Zurich, Zurich, Switzerland.
Christian BreymannDepartment of Obstetrics and Gynaecology, University Hospital Zurich, Obstetric Research, Feto- Maternal Haematology Research Group, Zurich, Switzerland.
Simon P HoerstrupInstitute for Regenerative Medicine (IREM), University of Zurich, Zurich, Switzerland.
Maximilian Y EmmertInstitute for Regenerative Medicine (IREM), University of Zurich, Zurich, Switzerland.
Swiss Institute for Regenerative Medicine · CHUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hemocompatibility of cardiovascular implants represents a major clinical challenge and, to date, optimal antithrombotic properties are lacking. Next-generation tissue-engineered heart valves (TEHVs) made from human-cell-derived tissue-engineered extracellular matrices (hTEMs) demonstrated their recellularization capacity

Indexed as

anti-coagulationendothelial colony forming cellendothelial progenitor cellhemocomaptibilityHPLhuman cell-derived tissue-engineered matricesscratch assaytranscatheter tissue-engineered valve

Identifiers

PMID35433657
PMCPMC9008229
OpenAlexW4220682905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.